The Patent Finder

Abivax

31 patents currently held · Updated Nov 21, 2026
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Dec 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 25, 2026
    The maintenance fee for A New Quinoline Derivative for Use in the Treatment and Prevention of Viral Infections (US 10,329,317) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
  • 1 fee due Feb 28, 2027
    The maintenance fee for Aryl-N-Aryl Derivatives for Treating a RNA Virus Infection (US 11,739,073) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
  • 1 fee due Apr 8, 2027
    The maintenance fee for Quinoline Derivatives for the Treatment of Inflammatory Diseases (US 10,435,370) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
  • 2 fees due May 5 to 28, 2027 · next May 5
  • 1 fee due Jul 21, 2027
    The maintenance fee for Compounds for Use as Therapeutic Agents Affecting P53 Expression And/Or Activity (US 10,538,485) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,211,861Compositions for and methods of enhancing the immune response to antigens
In force
 · USPTO record
In forceUSPTO record
US 8,207,135Compositions for and methods of enhancing the immune response to antigens
In force
 · USPTO record
In forceUSPTO record
US 10,253,020Compounds for Preventing, Inhibiting, or Treating Cancer, Aids And/Or Premature Aging
In force
 · Medium confidence
In forceMedium confidence
US 10,683,284Compounds for Preventing, Inhibiting, or Treating Cancer, Aids And/Or Premature Aging
In force
 · Low confidence
In forceLow confidence
US 10,975,063Compound, and Production Method Thereof, and Methods of Treatment Using the Compound
In force
 · Low confidence
In forceLow confidence
US 11,014,918Compounds and Pharmaceutical Compositions Containing at Least One of the Compounds
In force
 · Low confidence
In forceLow confidence
US 10,538,485Compounds for Use as Therapeutic Agents Affecting P53 Expression And/Or Activity
In force
 · High confidence
In forceHigh confidence
US 10,717,724Compounds Useful for Treating Cancer
In force
 · High confidence
In forceHigh confidence
US 10,870,671Method of preparation of alpha galactosyl ceramides compounds
In force
 · USPTO record
In forceUSPTO record
US 9,827,237Compounds Useful for Treating Diseases Caused by Retroviruses
In force
 · High confidence
In forceHigh confidence
10 of 31 patents shown.
Pro members see all 31.
Pro members: see all 31 patents
Also on record, not counted in the 31: 6 patents in force now held by others · 9 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

10 pending · 2 abandoned · 2 no status recorded

Showing 1 to 10 of 14, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/973,608In Vitro or Ex Vivo Methods for Screening a Quinoline DerivativeDec 9, 2024Pending
18/893,339Combination of 8-Chloro-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-Amine and Its Derivatives with a S1P Receptor ModulatorSep 23, 2024Pending
18/435,619Compounds for Preventing, Inhibiting, or Treating Cancer, Aids And/Or Premature AgingFeb 7, 2024Pending
18/832,670Combination of 8-Chloro-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-Amine and Its Derivatives with a Jak InhibitorJan 20, 2023Pending
18/729,018Combination of 8-Chloro-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-Amine and Its Derivatives with a S1P Receptor ModulatorJan 12, 2023Pending
18/722,995Method of Preparation of 1-(N-(QUINOLIN-2-YL)-(PHENYLAMINO)-1-Deoxy-BETA-D-GLUCOPYRANURONIC Acid DerivativesDec 20, 2022Pending
18/284,253Preparation Method of Quinoline Derivative CompoundsMar 23, 2022Pending
17/327,079Compounds for Preventing, Inhibiting, or Treating Cancer, Aids And/Or Premature AgingMay 21, 2021Abandoned
17/913,063Mar 19, 2021No status recorded
17/796,834Amorphous Solid Dispersion of 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINEJan 29, 2021Pending
10 of 14 applications shown.
Pro members see all 14 published applications.
Pro members: see all 14 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited